Benzinga's Top Initiations
- Canaccord Genuity initiated coverage on Irhythm Technologies Inc (NASDAQ: IRTC) with a Buy rating. The price target for Irhythm Technologies is set to $31. Irhythm Technologies shares closed at $24.23 on Friday.
- Analysts at Oppenheimer initiated coverage of Forterra Inc (NASDAQ: FRTA) with an Outperform rating. The price target for Forterra is set to $23. Forterra shares closed at $18.41 on Friday.
- Analysts at Leerink Swann assumed coverage on Veracyte Inc (NASDAQ: VCYT) with an Outperform rating. The price target for Veracyte is set to $12. Veracyte shares closed at $7.00 on Friday.
- Analysts at KeyBanc initiated coverage on MedEquities Realty Trust Inc (NYSE: MRT) with an Overweight rating. MedEquities Realty Trust shares closed at $10.57 on Friday.
- Analysts at Jefferies initiated coverage on DTE Energy Co (NYSE: DTE) with a Buy rating. The price target for DTE Energy is set to $102. DTE Energy shares closed at $90.97 on Friday.
- Analysts at UBS initiated coverage on Conagra Brands Inc (NYSE: CAG) with a Neutral rating. Conagra shares closed at $34.93 on Friday.
- Credit Suisse assumed coverage on First Solar, Inc. (NASDAQ: FSLR) with a Neutral rating. The price target for First Solar is set to $50. First Solar shares closed at $32.06 on Friday.
- Analysts at Stifel Nicolaus initiated coverage on Gilead Sciences, Inc. (NASDAQ: GILD) with a Buy rating. The price target for Gilead Sciences is set to $100. Gilead Sciences shares closed at $76.42 on Friday.
- Analysts at Barclays initiated coverage on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) with an Equal-Weight rating. The price target for Teva is set to $46. Teva shares closed at $40.65 on Friday.
- Credit Suisse assumed coverage on Royal Bank of Canada (NYSE: RY) with an Outperform rating. Royal Bank of Canada shares closed at $63.47 on Friday.
Latest Ratings for VCYT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 2019 | Initiates Coverage On | Buy | ||
| Jul 2019 | Initiates Coverage On | Buy | ||
| Nov 2018 | Downgrades | Buy | Neutral |
View More Analyst Ratings for VCYT
View the Latest Analyst Ratings
Posted-In: Top InitiationsInitiation Analyst Ratings
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
